January 9, 2025 - 02:52

Quantum computing stocks faced a steep decline on Wednesday as industry leader Jensen Huang, CEO of Nvidia, expressed skepticism about the near-term viability of practical quantum computers. Huang's assertion that "useful quantum computers" are still approximately 20 years away sent shockwaves through the market, leading to massive sell-offs among key players in the sector.
Rigetti Computing, IonQ Inc., and Quantum Computing saw their stock prices plummet by over 40% during the trading session, reflecting investor concerns about the long timeline for quantum technology to become commercially viable.
The fallout from Huang's comments has left investors reevaluating their positions within the quantum computing space, raising questions about the future of this emerging technology. As the market reacts, other companies such as D-Wave Quantum Inc. and Vir Biotechnology, Inc. are also catching attention, indicating a broader shift in focus among investors. The uncertainty surrounding quantum computing continues to loom large, with industry experts weighing in on the implications of these developments.
March 20, 2026 - 05:04
ECB follows Bank of England with interest rate hold as Iran war intensifiesThe European Central Bank (ECB) has opted to leave its key interest rates unchanged, maintaining a pause in its historic tightening cycle. This decision mirrors the recent move by the Bank of...
March 19, 2026 - 04:53
Most Californians Expect Little Change to Their Finances Despite Economic UncertaintyA new survey reveals a striking contrast in the financial outlook of California residents. While an overwhelming majority believe the state`s economy is headed for difficult times and feel their...
March 18, 2026 - 04:39
Nvidia CEO Huang says company sees more than $1 trillion in sales through 2027Nvidia CEO Jensen Huang has provided further clarity on the company`s staggering financial outlook, solidifying expectations for sales to exceed $1 trillion through the year 2027. This projection...
March 17, 2026 - 18:14
Eli Lilly Falls 5% — FDA Oral Obesity Pill Decision and Novo Nordisk Rivalry Weigh on SharesEli Lilly`s stock experienced a significant decline in Tuesday trading, dropping approximately 5% to around $937 per share. This downturn extends a challenging period for the pharmaceutical giant,...